FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Ascendis Pharma A/S Stock AnalysisComprehensive stock analysis for Ascendis Pharma A/S (ASND) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisASND
ASND
Ascendis Pharma A/S
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ASND
Home🔹Stocks🔹Ascendis Pharma A/S

Ascendis Pharma A/S

ASND•NASDAQ

Ascendis Pharma A/S

ASND•NASDAQ
Market cap
$15.80B
Sentiment

Your view on ASND

Mkt Cap
$15.80B
Sentiment
Your view
ASND
Ascendis Pharma A/S
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ASND
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Ascendis Pharma A/S

Industry
Biotechnology
Sector
Healthcare
CEO
Jan Moller Mikkelsen
Headquarters
Tuborg Boulevard 12, Hellerup, DK
Industry
Biotechnology
Sector
Healthcare
CEO
Jan Moller Mikkelsen
Headquarters
Tuborg Boulevard 12, Hellerup, DK
Description

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News